Ameet Nathwani

As a physician and seasoned drug developer, Ameet was attracted to become the Chief Executive Officer of Dewpoint Therapeutics by the cutting-edge science of condensates, which might hold the key to the causes underlying many of the most challenging diseases, and the possibilities this offers to create the next generation of breakthrough medicines. At Dewpoint, he is not only excited by the innumerable scientific possibilities, but also by the opportunity to build a global company that connects brilliant minds from diverse backgrounds into a team passionate to have a huge impact on human health.

Ameet has more than 25 years of experience in the pharmaceutical industry and has been responsible for the development of more than 20 drugs, four of which went on to become blockbusters. Before joining Dewpoint, he was an Executive Committee member at Sanofi SA, where he served as Chief Medical Officer and Chief Digital Officer and was responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes across the portfolio. Prior to Sanofi, he was the Global Head of Medical Affairs and a member of the Pharma Executive Committee at Novartis Pharma AG, where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capabilities. Over his 11 years at Novartis, Ameet held senior development and commercial positions including Global Head of the Critical Care Business Franchise, Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise. He also served in senior roles in R&D at GlaxoSmithKline, SmithKline Beecham and Glaxo Group Research in both the United Kingdom and United States.

Ameet earned his medical degree from the University of London, specialized in cardiology and intensive care medicine, and holds a Master of Business Administration. Away from work, he enjoys spending time with his family, sports, art and music.

Follow Ameet on Linkedin